Table 1.
Summary of the clinical characteristics of the study population.
| Characteristics | MRONJ Patients n = 63 |
|---|---|
| Age (years) (mean ± SD) * | 69.33 ± 11.06 |
| Sex | |
| Female | 46 |
| Male | 17 |
| Duration of treatment (months) (mean ± SD) * | 46.42 ± 39.77 |
| Disorder * | |
| Breast cancer | 26 |
| Prostate cancer | 11 |
| Myeloma multiplex | 11 |
| Osteoporosis | 7 |
| Lung cancer | 2 |
| Melanoma malignum | 1 |
| Colon cancer | 1 |
| Cervical cancer | 1 |
| Chemotherapy * | |
| Yes | 38 |
| No | 22 |
| Hormone deprivation therapy | |
| Yes | 32 |
| No | 28 |
| Antiresorptive agent *, ** | |
| Alendronate (p.o.) | 1 |
| Ibandronate (p.o.) | 4 |
| Risedronate (p.o.) | 1 |
| Zoledronate (iv./inj.) | 29 |
| Denosumab (inj.) | 29 |
| MRONJ localization *, *** | |
| Maxilla | 19 |
| Mandibula | 42 |
| MRONJ stage *, **** | |
| 1 | 1 |
| 2 | 44 |
| 3 | 15 |
* There were no available clinical data for three patients. ** Four patients had both bisphosphonate and denosumab. *** One patient had both maxillar and mandibular involvement. **** Based on the American Association of Oral and Maxillofacial Surgeons’(AAOMS) Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 update.